New generation baldness drugs send shares of biotechnology companies soaring

While shares of biotechnology companies developing new generation baldness drugs are rising rapidly, analysts say that the hair loss market could be the next big growth area of ​​the pharmaceutical industry. The development of new drugs for hair loss, which affects approximately 50 million men and 30 million women in the USA, leads to remarkable increases in the stocks of biotechnology companies. While the shares of companies such as Veradermics, Absci and Cosmo are rising rapidly, analysts predict that the market may reach a size of billions of dollars.

Shares are rising fast

While the shares of Veradermics, which went public in February, have gained approximately 500 percent in value since the beginning of the year, the shares of the artificial intelligence-supported drug development company Absci have more than doubled in 2026. Another notable player in the industry is Cosmo, based in Switzerland. The fact that the topical treatment called "clascoterone" developed by the company gave positive results in male pattern hair loss strengthened the possibility of the drug coming to the market.